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Abstract
In the United Kingdom, survival of prostate cancer patients has improved since the 1990s. A deprivation gap in survival
(better survival for the least deprived compared with the most deprived) has been reported but it is not known if differential
distribution of earlier age or lower grade disease at diagnosis might explain such patterns. We therefore investigated the
impact of age and Gleason grade at diagnosis on the deprivation gap in survival of prostate cancer patients over time.
Incident cases of prostate cancer (ICD-10 C61) from the West of Scotland were extracted from the Scottish Cancer Registry
from 1991 to 2007. Socio-economic circumstances were measured using the Scottish Index for Multiple Deprivation 2004
(SIMD). Age and deprivation specific mortality rates were obtained from the General Registrar Office for Scotland (GRO(S)).
The survival gradient across the five deprivation categories was estimated with linear regression, weighted by the variance
of the relative survival estimate. We examined the data for 15,292 adults diagnosed with prostate cancer between 1991 and
2007. Despite substantial improvements in survival of prostate cancer patients, a deprivation gap persists throughout the
three periods of diagnoses. The deprivation gap in five year relative survival widened from24.76 in 1991–1996 to210.08 in
2003–2007. On age and grade-specific analyses, a significant deprivation gap in five year survival existed between all age
groups except among patients’ age $75 and both low and high grade disease. On multivariate analyses, deprivation was
significantly associated with increased excess risk of death (RER 1.48, 95% CI 1.31–1.68, p-value,0.001) independent of age,
Gleason grade and period of diagnosis. The deprivation gap in survival from prostate cancer cannot be wholly explained by
socio-economic differentials in early detection of disease. Further research is needed to understand whether differences in
comorbidities or treatment explain inequalities in prostate cancer outcomes.
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Introduction
Survival of patients with prostate cancer has improved
significantly since the 1990s in many Western countries.
Improvements in survival have been attributed to greater detection
of early, localised disease and advances in treatment. Despite
substantial improvements in survival of patients with prostate
cancer, however, significant disparities in survival have been
observed between socio-economic and racial groups [1,2].
In the UK, a deprivation gap in survival of men with prostate
cancer (better survival for the least deprived compared with the
most deprived) has been reported previously in studies carried out
in England, Wales and Scotland [3,4]. The deprivation gap in five-
year survival from prostate cancer in England and Wales increased
from 21.2% (1.2% worse survival in the most deprived patients as
compared to the least deprived) in 1986–1990 to 27.2% in 1996–
1999 [3]. In Scotland, although the relative survival of prostate
cancer patients improved 11% on average every five years during
the period 1986–2000 [4], the deprivation gap has also increased
and the difference in relative survival between the least deprived
and the most deprived was similar to that in other parts of the UK,
at 26.9% during the period 1996–2000 [4].
In the United States, both socio-economic and racial inequal-
ities in survival have been attributed to delayed diagnosis and less
aggressive treatment [2,5]. Choice of treatment may also have a
substantial role in the observed survival trends as after a diagnosis
of prostate cancer men from low socio-economic groups are
substantially less likely to be treated with radical surgery or
radiotherapy [6]. It has also been suggested that socio-economic
survival differences may be explained by differences in age at
presentation; variations in aggressiveness and stage of disease at
the time of diagnosis; or by inequalities in access to health care
services between socio-economic groups [4]. There are important
practical differences in addressing each explanation, ranging from
better public health promotion to reconfiguration of health
services to ensure equity in referral and access to specialist
services. However, the effect of these factors on the observed
deprivation gap in survival remains unclear and not well
researched.
The aim of our study was to examine the overall and
deprivation-specific survival trends for men with prostate cancer
in the West of Scotland and to determine whether age or Gleason
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grade at diagnosis explained any difference in survival between
socio-economic groups.
Materials and Methods
Incidence data
We examined the data of adults (aged 15–100 years) diagnosed
with a first, primary (excluding non-melanoma skin cancer)
malignant neoplasm of the prostate during 1991–2007 in the
West of Scotland, using the International Classification of Diseases
(ICD) 10 code C61 for prostate cancer. We used the data of all
incident prostate cancer cases from 1st January 1991 to 31st
December 2007 and followed-up till 31st December 2008, as this
was the most recent year of complete survival data available at the
time of this analysis. Incidence data were linked to death records
provided by the General Registrar Office for Scotland (GRO(S)).
The vital status of all patients was considered to be known up to
31st December 2008. Patients identified from death certificate
records only were excluded (n= 225, 0.01% of all registered
records) from this analysis. This is because they had zero survival
due to having the same incidence and death dates. Thirty patients
belonging to areas other than the West of Scotland and one patient
older than 100 years were also excluded from this analysis.
Socio-economic status of individuals was assigned by matching
their postcode of residence at diagnosis to the Scottish Index of
Multiple Deprivation (SIMD) 2004 score. SIMD is an area-based
measure of socio-economic circumstances that ranks small
geographic areas of Scotland (datazones) from 1 (most deprived)
to 6505 (least deprived) using 31 indicators that cover current
income, employment, health, education, housing and access [7].
The datazones are further grouped into national quintiles that
range from least deprived to the most deprived. The Gleason
grading system is known to be associated with prostatic cancer
prognosis [8] and was used to describe tumour morphology.
Gleason grade was extracted from the Scottish Cancer Registry
where available.
Ethical approval
Permission to use Scottish Cancer Registry data was given by
the Privacy Advisory Committee of the Information Services
Division of National Health Service National Services Scotland.
All relevant Caldicott Guardians granted permission for use of
their Cancer Registry data.
Statistical analysis
For relative survival analysis, we compared the survival in
prostate cancer patients with men of the same age, calendar year
and socio-economic group in Scotland.
Population life tables were obtained for the years 1991–2007
and we assumed that age and deprivation-specific survival was the
same in 2008 as 2007, because life tables for 2008 were not
available. We used all Ederer I, Ederer II and Hakulinen methods
Table 1. Baseline characteristics of prostate cancer patients registered in the West of Scotland from 1991–2007.
Total patients All deaths
n % n %
Total registered cases 15,549 _ 9,355 60.2
Patients not residing in the West of Scotland 30 _ 19 63.3
Zero survival or death certificate only (DCO) 226 _ _ _
Age more than 100 years at diagnosis 1 _ 1 100.0
Patients included in final analysis 15,292 9,109 59.7
Age at incidence (years)
Age ,65 2,984 19.5 1,086 11.9
Age 65–74 6,023 39.4 3,232 35.5
Age $75 6,285 41.1 4,791 52.6
Gleason Grade
Gleason ,7 4,065 37.2 1,421 27.1
Gleason = 7 2,231 20.4 756 14.4
Gleason 8–10 3,311 30.3 2,051 39.0
Unknown Gleason 1,316 12.1 1,026 19.5
SIMD 2004, Quintiles
1 (least deprived) 2,623 17.2 1,295 14.2
2 2,278 14.9 1,219 13.4
3 2,450 16.0 1,444 15.9
4 3,737 24.4 2,365 26.0
5 (most deprived) 4,202 27.5 2,786 30.6
Period of Diagnosis
1991–1996 4,369 28.6 3,855 42.3
1997–2002 5,474 35.8 3,580 39.3
2003–2007 5,449 35.6 1,674 18.4
Period of diagnosis was based on incidence date recorded in cancer registry.
doi:10.1371/journal.pone.0056184.t001
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to relative survival, as the results were identical with all three
methods so we presented the results of Ederer II method.
Age at diagnosis was categorised in three groups as ,65, 65–74
and $75 years. To explore the time trends in survival, year of
diagnosis was categorised into three categories as 1991–1996,
1997–2002 and 2003–2007. The rationale behind using these
categories of year of diagnosis was that Scottish Cancer Registry
started to record Gleason grade from 1st January 1997. Therefore,
by making these categories, grade specific analysis could be carried
out on all subjects in the two later periods. Gleason grade was
categorised as low (Gleason 2–6), intermediate (Gleason= 7) and
high grades (Gleason 8–10).
We estimated one, three and five year relative survival rates for
prostate cancer patients diagnosed in the West of Scotland by age,
deprivation quintile, Gleason grade and calendar period of
diagnosis. Relative survival is the ratio of the observed (absolute)
survival of prostate cancer patients and the survival that would
have been expected if the patient had had the same age and
deprivation specific mortality in each period (background popu-
lation mortality); a technique which has been used earlier in the
estimation of the deprivation gap in Scotland [4]. Survival
probabilities for cancer patients were estimated at 6 month
intervals from diagnosis to 5 years. Cumulative relative survival up
to 5 years after diagnosis was estimated for patients diagnosed in
calendar periods 1991–1996, 1997–2002 and 2003–2007.
Both cohort and complete approaches were used to estimate
observed survival. In the estimation of five year survival using the
cohort approach, all patients must have a potential follow-up of at
least five years. With the complete approach recently diagnosed
patients with less than 5 years follow-up can also be included in the
analysis along with those with potential follow-up of at least 5
years. Both techniques provided similar results and the complete
approach survival analyses are presented in this study.
Survival gradients across the five deprivation quintiles based on
SIMD score were estimated with linear regression, weighted by the
variance of the relative survival estimate [9] using STATA
software (StataCorp, version 11). The difference between the
relative survival rates fitted by the linear regression model for the
least deprived and the most deprived categories is presented as the
‘‘deprivation gap’’ in survival. The deprivation gap is reported as
negative (2) if the most deprived group has lower survival than the
least deprived. Average changes in the deprivation gap between
the three periods have also been reported, taking into account the
shorter duration of the final period (1 year shorter than the two
earlier periods).
To investigate the impact of age and Gleason grade of tumour
on the deprivation gap, the gap was estimated stratifying by age
Table 2. Trends in relative survival (%) of prostate cancer patients by period of diagnosis in the West of Scotland: 1991 to 2007.
Calendar period of diagnosis Average change (%)
Time since diagnosis 1991–1996 1997–2002 2003–2007 between periods
a
Survival, % (95% CI) Survival, % (95% CI) Survival, % (95% CI) (95% CI)
1 year 83.2 (81.7, 84.5) 90.9 (89.9, 91.9) 92.1 (91.2, 93.0) 4.5 (219.4,28.3)
3 years 67.4 (65.5, 69.2) 78.1 (76.5, 79.6) 83.1 (81.6, 84.6) 7.8 (213.1, 28.8)
5 years 58.2 (56.0, 60.3) 71.0 (69.1, 72.8) 78.6 (76.4, 80.8) 10.2 (28.9, 29.3)
a =Mean absolute change in relative survival between periods adjusted for deprivation.
doi:10.1371/journal.pone.0056184.t002
Figure 1. Deprivation gap in 5-year relative survival from prostate cancer from 1991–2007 in the West of Scotland.
doi:10.1371/journal.pone.0056184.g001
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and Gleason grade categories. The deprivation gap was estimated
by least-squares linear regression, weighted by the variance of each
of the relative survival estimate stratified by age and Gleason
grade. The significance was evaluated with a likelihood ratio test at
the 5% level.
To investigate the major determinants associated with mortality,
a full likelihood approach was used to model the excess mortality
[10]. This method estimates the excess risk of mortality associated
with prostate cancer as mortality of prostate cancer patients is
compared with a matched cohort using the background popula-
tion mortality. Age at diagnosis, Gleason grade, deprivation and
period of diagnosis were used as independent variables in
modelling excess risk of death. We analysed the effects of baseline
variables on survival using Cox proportional hazards models
[11,12].
Results
A total of 15,519 men were identified, who were registered with
a diagnosis of prostate cancer in the West of Scotland from 1991–
2007. Details of excluded cases are provided in table 1, a total of
15,292 patients diagnosed in the West of Scotland were included
in the final analysis. The proportion of men younger than 65 years
at diagnosis increased over the study period, from 15.4% between
the years 1991–1996 to 23.6% between the years 2003–2007 (X2,
p,0.001). The highest proportion of cases were observed in older
age groups, 39.4% of cases (n = 6,023) occurred in 65–75 years of
age and 41.1% of cases (n = 6,285) in men older than 75 years.
Mean age at incidence decreased during the same periods from
73.268.74 to 71.169.08. Overall, 17.2% of patients were in the
least deprived group while 27.5% were in the most deprived
group. Baseline characteristics of the study population are
described in table 1.
Regarding disease grade, more than half of the men (57.6%)
had either low grade (Gleason ,7) or intermediate grade disease
(Gleason= 7). Proportions of low grade disease significantly
increased during the study period while the proportion of
unknown grade patients significantly reduced from 16.7 in
1997–2002 to 7.7% in 2003–2007 (X2, p,0.001).
Both short and long term survival of prostate cancer patients
have improved since 1991 (table 2). Relative survival at 1 year
increased significantly from 83.2% in 1991–1996 to 92.1% in
2003–2007 (fitted, deprivation adjusted increase of 4.5% between
periods). Five year survival increased from 58.2% to 78.6% in men
over the same period, an average deprivation adjusted increase of
10.2% between six year periods. While five year survival increased
between both latter periods, there was a larger increase between
the first two periods from 1991–1996 to 1997–2002 (11.8%) and a
relatively smaller increase (7.6%) in survival between the two later
periods (Table 2).
Despite substantial improvements in survival of prostate cancer
patients, there was a deprivation gap in each of the three periods
of diagnoses (Figure 1). Large improvements in survival occurred
over time in all socio-economic groups. The deprivation gap was
smaller in 1991–1996 and widened during later periods, due to
larger improvements in survival among the least deprived group.
There was little change in the deprivation gap in one year and
three year survival over time but the deprivation gap in five year
survival increased to a greater extent, from24.76 in 1991–1996 to
29.08 in 1996–2002, with a relatively small change to the most
recent period (table 3).
Further analysis was carried out to investigate the impact of age
and Gleason grade at diagnosis on the deprivation gap in survival.
For men younger than 65 years the deprivation gap was significant
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during the two earlier study periods, 1991–2002. Conversely, for
patients aged 65 years and older, no significant deprivation gap
was identified between 1991 and 2002 but a significant gap
appeared in the most recent period, 2003–07. This was 29.9% in
men aged 65–74 and 27.4% in men aged $75 years. Grade-
specific analysis from 1997 onwards (when information on grade
became available) showed a significant deprivation gap in five year
survival of 27% and 29% in men with low grade (Gleason 2–6)
and high grade disease (Gleason 8–10), respectively. There was no
significant deprivation gap for men with intermediate grade
disease (Gleason= 7) (table 4). A significant deprivation gap of
29% appeared in 2003–07 for patients with unknown Gleason
grade.
Deprivation was associated with increased risk of death,
independent of age at incidence and period of diagnosis, for both
low grade (age-adjusted RER for most deprived compared with
least deprived= 2.61, 95% CI 1.09–6.26, p-value,0.001) and
high grade disease (RER=1.36, 95% CI 1.10–1.69, p-val-
ue,0.005) groups. No deprivation effect on risk of death was
observed for intermediate grade disease. During the later period
(2003–2007), an 81% reduction in the risk of death was observed
in low grade disease group, 61% reduction in the intermediate
group and 22% risk reduction in the high grade group (table 5).
The risk of death increased by 87% among those with unknown
grade in the later period compared to the earlier one.
Discussion
This study confirms that survival of patients with prostate
cancer has significantly improved in the West of Scotland since
1991. Despite this, socio-economic inequalities in survival of
prostate cancer patients increased in the most recent period of
observation. Socio-economic inequalities in survival were of a
similar magnitude at different ages and Gleason grades, suggesting
that the effects of earlier detection of prostate cancer – such as by
greater PSA testing - in less deprived populations are unlikely to
wholly explain them.
Temporal trends in survival
Improvements have been observed in both short term (1-year)
and long term survival (5-year) in the West of Scotland. Overall,
improvement in survival are consistent with reports from England
and Wales [3]. Survival of patients with prostate cancer has
improved during corresponding periods in many European
countries. Denmark for example, observed approximately 7%
improvement in five year survival between 1985–2004 [13].
Another recent report from Denmark also suggested similar
findings [14]. In the Netherlands, survival improved by approx-
imately 1.8% annually from 1989 to 2006 [15].
Disease related factors are affected by PSA testing, which can
partly explain both the increase in incidence and survival. The
introduction of PSA testing may have led to stage and grade
migration of prostate cancer [16]. This has resulted in a rapid shift
in the biological spectrum of the disease such that at a population
level prostate cancer is not necessarily the fatal and incurable
disease it once was. A higher proportion of individuals are now
diagnosed with localized, small volume and low grade prostate
tumours[17], which are treated aggressively and, ultimately, lead
to better survival.
In recent years, greater awareness among general practitioners
is another factor that might have contributed to better manage-
ment of patients. For instance, greater awareness of prostate
cancer may have increased demands for PSA testing by at younger
age men or family members of men diagnosed with prostate
cancer leading to higher detection [18]. More intensive monitor-
ing of patients after diagnosis could also have played a role in
better survival and lower mortality. Besides the possible benefits
associated with PSA testing, there is also a risk of over diagnosis
and treatment of asymptomatic cases of prostate cancer which
might have never manifested as clinically symptomatic disease
during their lifetime [16].
Another potential factor contributing to improvement in
survival is the improvement and advancement in treatment. The
effect of treatment per se on improved survival in this population is
difficult to quantify accurately with available data, however there
is some evidence from other regions that therapeutic treatment has
contributed in some way to the observed survival improvements
[19].
Socio-economic inequalities in survival
Despite the overall improvement in survival of prostate cancer
patients, socio-economic inequalities in survival of prostate cancer
patients remained persistent slightly increased over the periods
1997–2002 and 2003–2007. Estimates of one, three and five year
deprivation gaps in survival have been presented along with the
trends of these gaps over time. The concurrent increase in survival
differences between the least deprived and the most deprived men,
taken with the more rapid increase in incidence of low grade
Table 4. Deprivation gap in 5-year relative survival of prostate cancer patients by age, Gleason grade and calendar period in the
West of Scotland during 1991–2007.
Calendar period of diagnosisa
Characteristics 1991–1996 1997–2002 2003–2007
Deprivation gap (%) (95% CI) Deprivation gap (%) (95% CI) Deprivation gap (%) (95% CI)
Age ,65 213.6 (223.24, 23.95) 213.32 (216.23,210.41) 27.72 (224.49, 9.05)
Age 65–74 25.36 (216.28, 5.56) 211.48 (213.20, 9.76) 29.92 (212.11, 27.73)
Age $75 2.00 (21.65, 5.66) 21.44 (212.22, 9.34) 27.36 (212.32, 22.40)
Gleason ,7 _ _ 26.64 (211.82,21.46) 26.88 (212.95, 20.80)
Gleason = 7 _ _ 20.4 (27.16, 6.36) 3.92 (26.47, 14.31)
Gleason 8–10 _ _ 210.12 (216.63, 23.61) 28.76 (220.37,2.85)
Unknown Gleason _ _ 21.8 (214.75,11.14) 28.76 (213.72,23.80)
a = Relative Survival estimated by complete approach.
doi:10.1371/journal.pone.0056184.t004
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disease among the least deprived group may suggests that
individuals from higher socio-economic groups had greater access
to PSA testing during these recent periods [17]. The deprivation
gap in survival for prostate cancer patients has been widening as
reported earlier from Scottish national data [4].
Socio-economic differences in survival have been observed in
many countries including Australia [20], New Zealand [21],
England and Wales [3] and the USA [5]. In England and Wales,
recent improvements in survival of many adult cancers including
prostate has been more marked for the least deprived groups
compared with the most deprived [9]. One of the major aims of
the NHS Cancer Plan, implemented in 2000 in England and
Wales, was to tackle inequalities in cancer survival. However, a
recent study examined the survival differences among affluent and
deprived cancer patients before and after the plan and reported
that there is very little variation in the deprivation gap in the 10
years after the implementation of the NHS Cancer Plan [22].
Several factors can contribute towards lower survival among
more deprived men including older age, advanced stage and
aggressive disease at presentation, higher prevalence of comor-
bidities and unhealthy lifestyle habits. The pattern of prostate
cancer presentation among deprived men characterized by lower
uptake of PSA and late diagnosis with advanced stage disease has
not changed over the years [23]. Whether the lower testing rate is
due to the lack of availability of the test from the General
Practitioners or the men in more deprived groups do not simply
come forward for testing need to be further investigated.
Some studies have attributed the socio-economic inequalities in
survival to higher levels of comorbidity among more deprived
patients (Clarke, 2008). Along with comorbidity, there are
numerous other factors that can contribute to socio-economic
inequalities in survival. For example, risk behaviours such as heavy
smoking or alcohol intake, which are more prevalent among the
most deprived patients, could explain some of the observed
differences in [24,25].
Although plausible, such explanations may not be consistent
with our findings. Age and deprivation specific background
population mortality rates were used to estimate relative survival
adjusted for differentials in comorbidity between socio-economic
groups. Differential comorbidity can only contribute to socio-
economic inequalities in relative survival only if they produce
additional disease-specific effects, such as altering response to
treatment [26]. Comorbidity can partly explain why non-
metastatic prostate cancer patients in England from poorer
socio-economic backgrounds were less likely to receive aggressive
surgical or radiological treatment compared with the least
deprived population group [27] . If differential co-morbidity
between these groups of prostate cancer patients explains
persistent or widening deprivation gap in survival, it would imply
that the impact of comorbidity on treatment (or outcome)
increased more among the most deprived than the least deprived
[26]. Since our findings show that cancer survival improved more
rapidly for the least deprived groups, socio-economic differences in
the diagnosis of prostate cancer and/or treatment of the disease
rather than comorbidity may be the more plausible potential
explanation of survival differences between social groups.
Age, Gleason grade at diagnosis and deprivation gap in
survival
Age and Gleason grade are considered to be strong predictors of
prognosis of prostate cancer patients. Large improvements in
survival were observed among those diagnosed with low grade
disease (Gleason ,7). The risk of death significantly reduced
among men with low grade disease in the most recent period
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(2003–2007) compared with earlier period (1997–2002). A
reduction of 80% in the excess risk of death in the most recent
period, suggests that the biological spectrum of prostate cancer has
changed over time and in more recent years, we are treating an
entirely new disease which is perhaps a very low risk cancer.
Despite the largest improvement in survival in this disease group,
more than double the risk of death was observed for the most
deprived group compared with the least deprived.
In this dataset, least deprived were more likely to be diagnosed
at a younger age and with lower grade. Age and Gleason grade-
specific analysis show some reduction in deprivation gap in
survival among younger men. However, there were no significant
changes in size of deprivation gap within both low and high grade
disease groups. This suggests that there may be disparities among
different socio-economic groups other than the difference in age
and disease grade at presentation.
Stage at diagnosis is also an important factor associated with the
survival of prostate cancer patients [24]. For example in the US,
Black men have poorer survival compared to Whites and one of
the explanations for that is the relatively late presentation by Black
men with advanced and metastatic disease at diagnosis. Delayed
presentation by low socio-economic groups is also considered a
contributory factor in socio-economic inequalities in cancer
survival in the UK. However, the hard evidence on this for
prostate cancer in the UK is still sparse. There is some evidence
from recent studies investigating the impact of race in clinical
presentation of prostate cancer in UK, but no significant
differences were observed between White and Black men’s age,
disease grade and stage at presentation [28,29]. Unfortunately,
disease stage information was not present in the Scottish Cancer
Registry data, so the role of disease stage in the existing
deprivation gap in survival could not be investigated.
Strengths and limitations of this research
Scotland Cancer Registry data for the West of Scotland was
used for this analysis providing a fairly large sample with long
follow-up of patients to carry out this analysis. Different techniques
were used to estimate the relative survival, i.e. cohort and
complete approach and both produced identical results. Those
whose prostate cancer diagnosis was only made after death or who
died on the day of diagnosis were excluded from this analysis. Such
patients comprised a small proportion of the study population
(n = 226, 0.01%). Exclusion of these cases from the analysis does
not explain the existing and widening deprivation gap in relative
survival for multiple reasons. First, there was no significant
difference in distribution of these cases between socio-economic
groups. Secondly, the proportion of patients excluded from the
analysis is very small to have any significant impact on the
estimates provided in this analysis.
The SIMD was used as a proxy measure of socio-economic
circumstances of prostate cancer patients in the present analysis.
As with all the area-based measures of deprivation, it assumes that
all individuals living in a given geographical area experience the
same level of deprivation and other associated factors. Individual
level data such as level of education, occupation and income can
provide stronger evidence of socio-economic circumstances;
however, these data are not routinely collected in cancer registries.
Earlier studies carried out in different regions of the UK, despite
the use of different area-based measures, also provided similar
results that the least deprived have better survival compared with
the most deprived, which suggests that these findings are not just
due to the measurement index. In addition, race has been widely
used as a measure of socio-economic circumstances in the US and
provided quite similar results suggesting that individuals from
poorer background experience worse survival. Another important
limitation is the unavailability of information on the stage of the
cancer and on comorbidities in the Scottish Cancer Registry, both
of which are well known prognostic factors in survival of patients.
Conclusion
The substantial improvements in survival from prostate cancer
are encouraging but persisting socio-economic inequalities remain.
These seem unlikely to be explained by greater use of PSA to
detect early prostate cancer in more affluent populations. Further
research is needed to explore the interactions of differentials in
comorbidities and treatment choice for prostate cancer in
persistent or widening deprivation gap in prostate cancer survival.
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